TELO Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

With a distinguished career in age-related medicine, including as the Chief Wellness Officer of the Cleveland Clinic, Dr. Roizen will provide direction to Telomir’s senior management and advise on medical and scientific matters, leveraging his extensive background in wellness, longevity, and age-reversal. His appointment reflects Telomir’s commitment to quality and innovation as it pursues potential treatments aimed at extending human life beyond what is currently possible.

A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures. He co-founded RealAge Inc., a consumer-health media company and provider of personalized health information and management tools where he maintains the role on its Advisory Board. He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years. He also served as the editor of several medical journals before being named the Chief Wellness Officer of the Cleveland Clinic in 2007. In addition to his professional experience, Dr. Roizen has published several best-selling books, including four #1 New York Times bestsellers (and 9 in the top 10) that have been translated into as many as 44 languages. He has also authored more than 195 peer-reviewed scientific papers. Dr. Roizen has been awarded 14 U.S. patents as well as many foreign patents, including RELISTOR® (methylnaltrexone bromide), a drug he co-invented which went on to receive FDA approval.

Pre-clinical studies suggest that the Company’s TELOMIR-1 product candidate may have the potential to protect stem cells in the body by reducing the overload of metals such as zinc and copper that accompany age-related inflammatory conditions and certain cancers. This metal imbalance may impact the length of telomeres (which protect the ends of chromosomes from becoming frayed or tangled) in stem cells and impact their ability to sustain self-renewal, which in turn could lead to reversal of age-related decline.

"I've dedicated my career to unraveling the molecular mechanisms of aging and developing interventions to promote healthy longevity," commented Dr. Roizen. "Stem cells that could repair the heart, blood vessels, brain, joints and other critical organs to a healthier state require elongating telomeres. TELOMIR-1 may be a key to telomere regeneration, and subsequent benefits that have the effect of age reversing, by enabling the ability to produce more stem cells, resulting in an individual’s ability to repair oneself with oral medication. I believe Telomir's technology has tremendous potential to delay, prevent, or even reverse age-related decline. I'm eager to work with the team to make telomere therapies a reality."

Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry. Having Dr. Roizen on our team, one of the foremost experts in longevity science, demonstrates our commitment to making therapies to extend healthy lifespan a reality. We look forward to his continued contributions to our efforts.”

To be included in the Telomir Pharmaceuticals email distribution list, please email telomir@kcsa.com with TELO in the subject line.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal. Telomir’s goal is to develop and commercialize TELOMIR-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and ultimately post-chemotherapy recovery and a broader range of other age-related inflammatory conditions such as osteoarthritis.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Telomir’s technologies potential in reversing age-related decline and TELOMIR-1’s ability to result in an individual’s ability to repair oneself by using TELOMIR-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company’s control) that could cause actual results (including the timing for and results of the Company’s pre-clinical investigation and potential clinical trials and the potential benefits of Dr. Roizen’s association with the Company) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning Telomir's programs and operations are described in additional detail in its registration statement on Form S-1 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company’s website at https://ir.telomirpharma.com. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For further information, please contact:

KCSA Strategic Communications Phil Carlsontelomir@kcsa.comTelomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558